

**ALKEM LABORATORIES LTD.**

**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955  
• Email: contact@alkem.com • Website: www.alkemlabs.com  
• CIN: L00305MH1973PLC174201

13<sup>th</sup> February, 2026

To,

<b>The Corporate Relationship Department BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

Dear Sir(s)/ Madam,

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”).**

This is in furtherance to our earlier intimation dated 23<sup>rd</sup> December, 2022 with regard to the Shareholders’ Agreement entered into by the Company with Enzene Biosciences Limited, a subsidiary of the Company (“**Enzene**”), Eight Roads Ventures India Healthcare IV, L.P. (“**Eight Roads Ventures**”) and F-Prime Capital Partners Life Sciences Fund VI LP (“**F-Prime Capital**”) for acquisition of a minority stake by Eight Roads Ventures and F-Prime Capital in Enzene and intimation dated 11<sup>th</sup> August, 2023 informing the stock exchanges of the liability created on the Company pursuant to the said Shareholders’ Agreement.

Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby wish to inform you that an Amendment cum Supplemental Agreement dated 13<sup>th</sup> February, 2026 has been entered into by the Company with Enzene, Eight Roads Ventures, F-Prime Capital and ERVI Healthcare IV Holdings Limited (“**ERVI Healthcare**”) for: (a) the allotment of securities by Enzene to F-Prime Capital and ERVI Healthcare on a preferential basis by way of private placement; (b) the adherence by ERVI Healthcare to the terms of the said Shareholders’ Agreement; and (c) the amendment of certain provisions of the said Shareholders’ Agreement.

In this regard, the necessary disclosures/ information required to be submitted pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure I. A copy of this disclosure will be made available on the Company’s website in accordance with Regulation 30(8) of the SEBI Listing Regulations.

Kindly take the same on record.

Sincerely,  
For **Alkem Laboratories Limited**

**Manish Narang**  
**President – Legal, Company Secretary & Compliance Officer**

Encl: a/a



## ALKEM LABORATORIES LTD.

**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955  
• Email: contact@alkem.com • Website: www.alkemlabs.com  
• CIN: L00305MH1973PLC174201

### Annexure I

Sr. No.	Particulars	Remarks										
a.	If the listed entity is a party to the agreement: (i) details of the counterparties (including name and relationship with the listed entity);	1. Enzene Biosciences Limited, a Subsidiary of the Company (“Enzene”); 2. Eight Roads Ventures India Healthcare IV, L.P (“Eight Roads Ventures”); 3. F-Prime Capital Partners Life Sciences Fund VI LP (“F-Prime Capital”); 4. M/s ERVI Healthcare IV Holdings Limited (“ERVI Healthcare”); 5. Alkem Laboratories Limited (“Company”)										
b.	If listed entity is not a party to the agreement: (i) name of the party entering into such an agreement and the relationship with the listed entity; (ii) details of the counterparties to the agreement (including name and relationship with the listed entity); (iii) date of entering into the agreement.	NA										
c.	Purpose of entering into the agreement;	The Company has entered into an Amendment cum Supplemental Agreement with Enzene, Eight Roads Ventures, F-Prime Capital and ERVI Healthcare for: (a) the allotment of securities by Enzene to F-Prime and ERVI Healthcare on preferential basis by way of private placement; (b) the adherence by ERVI Healthcare to the terms of the said Shareholders’ Agreement; and (c) the amendment of certain provisions of the said Shareholders’ Agreement.										
d.	Shareholding, if any, in the entity with whom the agreement is executed;	<table border="1"> <thead> <tr> <th>Name of the entity</th> <th>% of total share capital of Enzene (on a fully diluted basis) post allotment</th> </tr> </thead> <tbody> <tr> <td>Alkem</td> <td>88.99</td> </tr> <tr> <td>Eight Roads</td> <td>5.42</td> </tr> <tr> <td>F-Prime</td> <td>1.87</td> </tr> <tr> <td>ERVI Healthcare</td> <td>0.71</td> </tr> </tbody> </table>	Name of the entity	% of total share capital of Enzene (on a fully diluted basis) post allotment	Alkem	88.99	Eight Roads	5.42	F-Prime	1.87	ERVI Healthcare	0.71
Name of the entity	% of total share capital of Enzene (on a fully diluted basis) post allotment											
Alkem	88.99											
Eight Roads	5.42											
F-Prime	1.87											
ERVI Healthcare	0.71											
e.	Significant terms of the agreement (in brief);	F-Prime and ERVI Healthcare to infuse aggregate amount of Rs. 26,16,25,003/- towards subscription of 5,58,302 Series B Compulsorily Convertible Preference Shares (‘Series B CCPS’) and 10 Equity Shares of Enzene.										
f.	Extent and the nature of impact on management or control of the listed entity;	NA										
g.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship;	One of the contracting party to the agreement i.e. Enzene, is a subsidiary of the Company.										



## ALKEM LABORATORIES LTD.

**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955  
• Email: contact@alkem.com • Website: www.alkemlabs.com  
• CIN: L00305MH1973PLC174201

h.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	The said transaction does not fall within the purview of related party transaction.									
i.	In case of issuance of shares to the parties, details of issue price, class of shares issued;	<p>Enzene to issue:</p> <p>(i) 1,30,451 Series B CCPS to F-Prime having face value of Rs. 10/- (Indian Rupees Ten) per share, each at a price of Rs. 468.60/- (Indian Rupees Four Hundred and Sixty Eight and Sixty Paise only) (including a premium of Rs. 458.60/- (Indian Rupees Four Hundred and Fifty Eight and Sixty Paise) per share), and</p> <p>(ii) 4,27,851 Series B CCPS having face value of Rs. 10/- (Indian Rupees Ten) per share, each at a price of Rs. 468.60/- (Indian Rupees Four Hundred and Sixty Eight and Sixty Paise only) (including a premium of Rs. 458.60/- (Indian Rupees Four Hundred and Fifty Eight and Sixty Paise) per share), and 10 equity shares having face value of Rs. 10/- (Indian Rupees Ten) per share, each at a price of Rs. 468.60/- (Indian Rupees Four Hundred and Sixty Eight and Sixty Paise only) (including a premium of Rs. 458.60/- (Indian Rupees Four Hundred and Fifty Eight and Sixty Paise) per share), to ERVI Healthcare.</p>									
j.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.;	NA									
k.	In case of rescission, amendment or alteration, listed entity shall disclose additional details to the stock exchange(s):	Yes									
	<table border="1"> <tr> <td data-bbox="272 1682 331 1993">i.</td> <td data-bbox="331 1682 775 1993">Name of parties to the agreement</td> <td data-bbox="775 1682 1433 1993">           1.Enzene Biosciences Limited, a Subsidiary of the Company (“Enzene”);            2.Eight Roads Ventures India Healthcare IV, L.P (“Eight Roads Ventures”);            3.F-Prime Capital Partners Life Sciences Fund VI LP (“F-Prime Capital”);            4.M/s ERVI Healthcare IV Holdings Limited (“ERV”);            5.Alkem Laboratories Limited (“Company”)         </td> </tr> <tr> <td data-bbox="272 1993 331 2035">ii</td> <td data-bbox="331 1993 775 2035">Nature of the agreement</td> <td data-bbox="775 1993 1433 2035">Amendment cum Supplemental Agreement</td> </tr> <tr> <td data-bbox="272 2035 331 2100">iii</td> <td data-bbox="331 2035 775 2100">Date of execution of the agreement</td> <td data-bbox="775 2035 1433 2100">13<sup>th</sup> February, 2026</td> </tr> </table>	i.	Name of parties to the agreement	1.Enzene Biosciences Limited, a Subsidiary of the Company (“Enzene”); 2.Eight Roads Ventures India Healthcare IV, L.P (“Eight Roads Ventures”); 3.F-Prime Capital Partners Life Sciences Fund VI LP (“F-Prime Capital”); 4.M/s ERVI Healthcare IV Holdings Limited (“ERV”); 5.Alkem Laboratories Limited (“Company”)	ii	Nature of the agreement	Amendment cum Supplemental Agreement	iii	Date of execution of the agreement	13 <sup>th</sup> February, 2026	
i.	Name of parties to the agreement	1.Enzene Biosciences Limited, a Subsidiary of the Company (“Enzene”); 2.Eight Roads Ventures India Healthcare IV, L.P (“Eight Roads Ventures”); 3.F-Prime Capital Partners Life Sciences Fund VI LP (“F-Prime Capital”); 4.M/s ERVI Healthcare IV Holdings Limited (“ERV”); 5.Alkem Laboratories Limited (“Company”)									
ii	Nature of the agreement	Amendment cum Supplemental Agreement									
iii	Date of execution of the agreement	13 <sup>th</sup> February, 2026									



**ALKEM LABORATORIES LTD.**

**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955  
• Email: contact@alkem.com • Website: www.alkemlabs.com  
• CIN: L00305MH1973PLC174201

	<p>iv Details and reasons for amendment or alteration and impact thereof (including impact on management or control and on the restriction or liability quantified earlier);</p>	<p><u>Reasons for amendment:</u></p> <p>Amendments are required to be made to the Shareholders Agreement: (a) for the adherence by ERVI Healthcare to the terms of the Shareholders' Agreement; and (b) consequent to the subscription of the below mentioned securities of Enzene on a preferential basis by way of private placement as under: (i) 1,30,451 Series B CCPS by F-Prime and (ii) 4,27,851 Series B CCPS and 10 equity shares by ERVI Healthcare.</p> <p><u>Details for amendment on the liability quantified earlier:</u></p> <p>N.A.</p>
	<p>v Reasons for rescission and impact thereof (including impact on management or control and on the restriction or liability quantified earlier).</p>	<p>NA</p>